Posted by Michael Wonder on 14 Jun 2023
CellCentric receives FDA fast track designation for relapsed refractory multiple myeloma drug
13 June 2023 - CellCentric has announced that the US FDA has granted its novel cancer drug, inobrodib, fast track designation for the treatment of patients with relapsed or refractory multiple myeloma.
It is a first in class drug, with a new mechanism of action. Inobrodib can be used by patients who have failed on other treatments, and in combination with existing standard of care drugs.
